Leo Pharma executive on EU progress: This is a huge milestone for us

Now that the CHMP has recommended approval for the eczema drug Adtralza, Leo Pharma can start preparing for the firm's most significant launch in years.
Leo Pharma Corporate EVP and Head of Global R&D Jörg Möller | Photo: Leo Pharma / PR
Leo Pharma Corporate EVP and Head of Global R&D Jörg Möller | Photo: Leo Pharma / PR
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

On Friday, Leo Pharma received an approval recommendation for the drug tralokinumab, which will be known as Adtralza onwards, for treating eczema. This is the culmination of five years' hard work, and for the the Danish dermatology company, it is the first time it has full control of a global launch relating to one of its biological drugs.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading